Exhibit 99.1


      CAUTIONARY STATEMENTS REGARDING "SAFE HARBOR" PROVISIONS
      OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995


     The Company is hereby filing a cautionary statement 
identifying important factors that could cause the Company's actual 
results to differ materially from those projected in forward 
looking statements of the Company made by, or on behalf of, the 
Company.

       Competitive factors including technological advances 
attained by competitors; patents granted to competitors; new 
products of competitors coming to the market; generic 
competition as the Company's products mature. 

       Increased pricing pressure both in the United States and 
abroad from managed care buyers, institutions and government 
agencies.

       Government laws and regulations affecting domestic and 
international operations including, among other laws and 
regulations, those resulting from healthcare reform 
initiatives at the state and federal level, as well as those 
relating to trade, monetary and fiscal policies, taxes, 
price controls, and possible nationalization.

       Patent positions can be highly uncertain and patent disputes 
are not unusual.  An adverse result in a patent dispute can 
preclude commercialization of products or negatively impact 
sales of existing products.

       Uncertainties of the FDA approval process and the regulatory 
approval processes of foreign countries, including, without 
limitation, delays in approval of new products.

       Difficulties in product development.  Pharmaceutical product 
development is highly uncertain.  Products that appear 
promising in the early phases of development may fail to 
reach market for numerous reasons.  They may be found to be 
ineffective or to have harmful side effects in clinical or 
pre-clinical testing, they may fail to receive the necessary 
regulatory approvals, they may turn out not to be 
economically feasible because of manufacturing costs or 
other factors or they may be precluded from 
commercialization by the proprietary rights of others.

       Recalls of pharmaceutical products as a consequence of 
previously unknown side-effects or for other reasons may 
occur.

       Significant litigation adverse to the Company.

       Fluctuations in interest rates and foreign currency exchange 
rates.





22533-1